VALTREX
LOE ApproachingNDAOralTabletPriority Review
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
Priority Review
VALTREX by GSK is α-herpes viruses [see microbiology ( )]. Approved for cold sores (herpes labialis), the initial episode of genital herpes in immunocompetent adults, recurrent episodes of genital herpes in immunocompetent adults and 5 more indications. First approved in 1995.
Drug data last refreshed 49m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALTREX is an oral antiviral medication approved in 1995 for the treatment of herpesvirus infections. The drug is a small molecule that inhibits viral DNA replication in herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It represents a foundational therapy in the antiviral treatment landscape.
$5MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending, indicating a maturing brand with potential team restructuring ahead.
Mechanism of Action
α-herpes viruses [see Microbiology ( )].
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.